Wednesday, July 8, 2026

biotech · Hematological or solid tumor malignancies or autoimmune diseases · Intracerebral Haemorrhage · IPSC

Century Therapeutics

Century Therapeutics is a biotech organization headquartered in Philadelphia, USA. It trades on NYSE under ticker IPSC. Primary therapeutic focus areas include Hematological or solid tumor malignancies or autoimmune dise

Philadelphia, USA HQ
2018 Founded
104 Employees
Public company Type
IPSC · NYSE Ticker
Company details
Status
Public
HQ
Philadelphia, USA
Founded
2018
Employees
104
Programs
10
Drugs
9
Patents
39
Clinical program

X-22 Smoking Cessation Product

Phase 2 · small molecule · Smoking Cessation

X-22 Smoking Cessation Product for Smoking Cessation is a Phase 2 program (small_molecule) at Century Therapeutics with 1 ClinicalTrials.gov record(s).

← All Century Therapeutics projects Phase 2 small molecule completed

Internal code X-22-201

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Century Therapeutics
Phase
Phase 2
Modality
small_molecule
Indication
Smoking Cessation
Status
completed
Trials
1

Clinical trials